Sorafenib for Advanced and Refractory Desmoid Tumors
Author(s) -
Mrinal M. Gounder,
Michelle R. Mahoney,
Brian A. Van Tine,
Vinod Ravi,
Steven Attia,
Hari A. Deshpande,
Abha A. Gupta,
Mohammed Milhem,
Robert M. Conry,
Sujana Movva,
Michael J. Pishvaian,
Richard F. Riedel,
Tarek Sabagh,
William D. Tap,
Natally Horvat,
Ethan Basch,
Lawrence H. Schwartz,
Robert G. Maki,
Narasimhan P. Agaram,
Robert A. Lefkowitz,
Yousef Mazaheri,
Rikiya Yamashita,
James R. Wright,
Amylou C. Dueck,
Gary K. Schwartz
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1805052
Subject(s) - sorafenib , refractory (planetary science) , medicine , oncology , materials science , hepatocellular carcinoma , metallurgy
Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom